Prognosis and treatment for aplastic anemia require tailoring based on which mutations patients have among a handful of leukemia-related genes, according to a new study from researchers including NHLBI's Dr. Neal S. Young.
News & Resources
NHLBI Media Availability: Largest Study of Gene Mutations in Aplastic Anemia May Help Optimize Treatment
Scientists have identified a group of genetic mutations in patients with aplastic anemia, which likely will help doctors optimize treatment for this rare and deadly blood condition. The study, appearing in the New England Journal of Medicine, could lead to tailor-made treatment plans for aplastic anemia patients as part of the emerging precision medicine movement. It is the largest study of its kind to examine gene mutations in aplastic anemia, the scientists note.
NHLBI Media Availability: Scientists develop method of producing large quantities of selectively labeled RNA molecules
Study opens door to new opportunities in medicine and research
WHAT: Scientists have developed an efficient method of producing substantial quantities of RNA molecules with selectively labeled regions, paving the way for more advanced research and medical applications. RNA — DNA's lesser-known partner molecule — plays a significant role not only in genetic activities but in many other biological functions like enzymatic processes. It also is an important research, medical diagnostic, and therapeutic tool.
Featured Fact Sheet
In 2010, Afia Donkor, a young woman from Canada, struggled to walk a few blocks from her home to a subway station in Montreal on her way to the airport. Suitcase in hand, she moved at a snail’s pace as she experienced severe exhaustion due to a flare-up of her sickle cell disease. One step at a time, she finally made it, propelled by the hope of a new treatment that awaited her at the other end of her journey to the United States. Read full fact sheet...
NHLBI's Dr. Toren Finkel joined a live radio panel discussion on the Diane Rehm Show to discuss his anti-aging research involving work on mice. Other panel members included National Institute on Aging's Dr. Mark Mattson and Massachusetts Institute of Technology's Leonard Guarente.